STOCK TITAN

Form 4: Dizon Romeo R reports purchase transactions in IRIX

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Dizon Romeo R reported open-market purchase transactions in a Form 4 filing for IRIX. The filing lists transactions totaling 2,200 shares at a weighted average price of $1.34 per share. Following the reported transactions, holdings were 118,690 shares.

Positive

  • None.

Negative

  • None.
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Dizon Romeo R

(Last) (First) (Middle)
1212 TERRA BELLA AVENUE

(Street)
MOUNTAIN VIEW CA 94043

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
IRIDEX CORP [ IRIX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Financial Officer
3. Date of Earliest Transaction (Month/Day/Year)
02/17/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 02/17/2026 P 1,000 A $1.37 118,690 D
Common Stock 02/17/2026 P 1,200 A $1.31 119,890 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
/s/ Nilo De Castro, Attorney-in-fact for Romeo R. Dizon 02/17/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider activity did IRIDEX (IRIX) disclose in this Form 4?

IRIDEX disclosed that its Chief Financial Officer, Romeo R. Dizon, bought common stock in the open market. On February 17, 2026, he executed two separate purchases totaling 2,200 shares, increasing his direct ownership position in the company.

How many IRIDEX (IRIX) shares did the CFO buy and at what prices?

Romeo R. Dizon purchased 1,000 IRIDEX common shares at $1.37 and 1,200 shares at $1.31 on February 17, 2026. These open-market transactions together added 2,200 shares to his personal holdings in the company.

What is the CFO’s total IRIDEX (IRIX) share ownership after these trades?

After the reported transactions, Chief Financial Officer Romeo R. Dizon directly owned 119,890 shares of IRIDEX common stock. This figure reflects his updated beneficial ownership following the combined purchase of 2,200 shares on February 17, 2026.

Were the IRIDEX (IRIX) insider transactions open-market purchases or another type?

The filing shows both transactions as open-market purchases, coded “P” for common stock. This indicates Romeo R. Dizon bought shares directly in the market or a private transaction rather than receiving them through options, grants, or other derivative instruments.

Does the IRIDEX (IRIX) Form 4 show direct or indirect ownership by the CFO?

The Form 4 lists the CFO’s ownership as direct, marked with code “D” for both transactions. This means the 119,890 IRIDEX shares reported after the purchases are held directly in Romeo R. Dizon’s name, not through an intermediary entity or trust.

What is the transaction date for the IRIDEX (IRIX) CFO share purchases?

Both insider purchases occurred on February 17, 2026. On that date, IRIDEX’s Chief Financial Officer, Romeo R. Dizon, executed two separate open-market trades in the company’s common stock at prices of $1.37 and $1.31 per share.
Iridex

NASDAQ:IRIX

IRIX Rankings

IRIX Latest News

IRIX Latest SEC Filings

IRIX Stock Data

24.24M
11.94M
Medical Devices
Electromedical & Electrotherapeutic Apparatus
Link
United States
MOUNTAIN VIEW